The Role of Route of Entry by Bacterial Antigens on Colonic T Cell Responses

细菌抗原进入途径对结肠 T 细胞反应的作用

基本信息

  • 批准号:
    9912712
  • 负责人:
  • 金额:
    $ 55.24万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2018
  • 资助国家:
    美国
  • 起止时间:
    2018-05-23 至 2023-04-30
  • 项目状态:
    已结题

项目摘要

Project Summary Effector T cell responses to pathogenic bacteria are crucial for protection from pathogens, but when directed toward non-pathogens, may underlie inappropriate responses driving disorders such as inflammatory bowel disease (IBD). Conversely, Foxp3+ regulatory T cell (Treg) responses to commensals enforce tolerance to prevent immune-mediated pathology such as IBD. The relative priority and context of gut bacterial interaction with the immune system remain significant gaps in our understanding. We observed that dysbiosis induces the formation of colonic goblet cell associated antigen passages (GAPs), providing an alternative route by which the immune system encounters gut resident bacteria. Further, we observed that gut resident bacteria taxa generally considered as tolerance-promoting can induce effector responses when encountered via colonic GAPs. Alternatively, we have found that antigen-specific peripheral (pTregs) largely recognize mucosal associated (MA) murine Helicobacter spp in vitro and in vivo, and that encounter of Helicobacter spp occurs continuously and is independent of GAPs. These data indicate that bacteria believed to be pathobionts can be potent inducers of pTregs during homeostasis, and in contrast, taxa believed to be tolerance inducing, Clostridia, are largely not encountered by the immune system in the steady state, but are encountered via colonic GAPs resulting in effector T cell responses. We hypothesize that the location and route of encounter of gut bacteria are important determinants of the outcome of immune responses and that the MA bacteria can play an important role in controlling the interactions and responses to gut resident bacteria encountered via colonic GAPs. In this proposal we will evaluate this hypothesis by: 1) defining the commensal antigens delivered via mucosal association (MA) and GAPs 2) defining the dendritic cell (DC) subsets involved in acquisition and presentation of mucosal associated and GAP delivered commensal antigens and 3) defining the effects of Helicobacter on the mucosal immune system and responses to GAP delivered antigens. Studies outlined in this proposal will fill the gaps in our understanding by identifying how specific bacterial taxa are encountered by the immune system and the subsequent immune responses. This knowledge can be leveraged to guide manipulations of the gut microbiota and the immune system to ‘reset’ chronic inflammatory responses and return to homeostasis.
项目总结

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

CHYI S HSIEH其他文献

CHYI S HSIEH的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('CHYI S HSIEH', 18)}}的其他基金

CAR-T cell treatment of CNS Autoimmunity
CAR-T细胞治疗中枢神经系统自身免疫
  • 批准号:
    10641913
  • 财政年份:
    2022
  • 资助金额:
    $ 55.24万
  • 项目类别:
CAR-T cell treatment of CNS Autoimmunity
CAR-T细胞治疗中枢神经系统自身免疫
  • 批准号:
    10539779
  • 财政年份:
    2022
  • 资助金额:
    $ 55.24万
  • 项目类别:
B cell-targeted CAR-T treatment of CNS Autoimmunity
B细胞靶向CAR-T治疗中枢神经系统自身免疫
  • 批准号:
    10514950
  • 财政年份:
    2022
  • 资助金额:
    $ 55.24万
  • 项目类别:
Immune interactions with commensal microbes in early life
生命早期与共生微生物的免疫相互作用
  • 批准号:
    10567936
  • 财政年份:
    2022
  • 资助金额:
    $ 55.24万
  • 项目类别:
B cell-targeted CAR-T treatment of CNS Autoimmunity
B细胞靶向CAR-T治疗中枢神经系统自身免疫
  • 批准号:
    10677698
  • 财政年份:
    2022
  • 资助金额:
    $ 55.24万
  • 项目类别:
Gut Intrinsic Inflammatory Responses
肠道内在炎症反应
  • 批准号:
    10614624
  • 财政年份:
    2021
  • 资助金额:
    $ 55.24万
  • 项目类别:
Gut Intrinsic Inflammatory Responses
肠道内在炎症反应
  • 批准号:
    10456984
  • 财政年份:
    2021
  • 资助金额:
    $ 55.24万
  • 项目类别:
Gut Intrinsic Inflammatory Responses
肠道内在炎症反应
  • 批准号:
    10282913
  • 财政年份:
    2021
  • 资助金额:
    $ 55.24万
  • 项目类别:
ROLE OF STRESS IN GUT IMMUNE INTERACTIONS WITH COMMENSAL BACTERIA
压力在肠道免疫与共生细菌相互作用中的作用
  • 批准号:
    10204715
  • 财政年份:
    2018
  • 资助金额:
    $ 55.24万
  • 项目类别:
The Role of Route of Entry by Bacterial Antigens on Colonic T Cell Responses
细菌抗原进入途径对结肠 T 细胞反应的作用
  • 批准号:
    10396536
  • 财政年份:
    2018
  • 资助金额:
    $ 55.24万
  • 项目类别:

相似海外基金

Defining MHC class I restricted antigen presentation to CD8 T cells in experimental AD and Tauopathy - Supplement
定义实验性 AD 和 Tau 病中 MHC I 类限制性抗原呈递至 CD8 T 细胞 - 补充
  • 批准号:
    10836880
  • 财政年份:
    2023
  • 资助金额:
    $ 55.24万
  • 项目类别:
Targeting MAL2-mediated endocytosis to enhance tumor cell antigen presentation
靶向 MAL2 介导的内吞作用以增强肿瘤细胞抗原呈递
  • 批准号:
    10734324
  • 财政年份:
    2023
  • 资助金额:
    $ 55.24万
  • 项目类别:
Antigen presentation to the adaptive immune system in the choroid contributes to ocular autoimmune disease
脉络膜中的适应性免疫系统的抗原呈递导致眼部自身免疫性疾病
  • 批准号:
    10740465
  • 财政年份:
    2023
  • 资助金额:
    $ 55.24万
  • 项目类别:
Investigation of Target Protein Degradation and Its Effect on Enhancing Cancer-Specific Antigen Presentation by Quantitative Mass Spectrometry
通过定量质谱研究靶蛋白降解及其对增强癌症特异性抗原呈递的影响
  • 批准号:
    23K04971
  • 财政年份:
    2023
  • 资助金额:
    $ 55.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Promoting cancer cells' antigen presentation for serving as better targets for T cell immunotherapy
促进癌细胞的抗原呈递,作为 T 细胞免疫治疗的更好靶点
  • 批准号:
    2885451
  • 财政年份:
    2023
  • 资助金额:
    $ 55.24万
  • 项目类别:
    Studentship
Targeting immunoproteasome-mediated antigen presentation in colorectal cancer immunotherapy
结直肠癌免疫治疗中靶向免疫蛋白酶体介导的抗原呈递
  • 批准号:
    10385926
  • 财政年份:
    2022
  • 资助金额:
    $ 55.24万
  • 项目类别:
Lipid Antigen Presentation as a Driver of T2D Inflammation
脂质抗原呈递作为 T2D 炎症的驱动因素
  • 批准号:
    10509043
  • 财政年份:
    2022
  • 资助金额:
    $ 55.24万
  • 项目类别:
Enhancing antigen presentation in triple negative breast cancers through CD40 agonist, Flt3 ligand, and anthracycline chemotherapy
通过 CD40 激动剂、Flt3 配体和蒽环类化疗增强三阴性乳腺癌的抗原呈递
  • 批准号:
    10704008
  • 财政年份:
    2022
  • 资助金额:
    $ 55.24万
  • 项目类别:
Sex Differences in lipid antigen presentation, impact of lipid antigen presentation on peripheral lipid metabolism
脂质抗原呈递的性别差异,脂质抗原呈递对外周脂质代谢的影响
  • 批准号:
    10818273
  • 财政年份:
    2022
  • 资助金额:
    $ 55.24万
  • 项目类别:
Enhancing antigen presentation in triple negative breast cancers through CD40 agonist, Flt3 ligand, and anthracycline chemotherapy
通过 CD40 激动剂、Flt3 配体和蒽环类化疗增强三阴性乳腺癌的抗原呈递
  • 批准号:
    10349397
  • 财政年份:
    2022
  • 资助金额:
    $ 55.24万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了